Moderna stock gains 1.08 percent as targets lag price
Published on 10/07/2026 at 17:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna stock (ISIN US60770K1079) was trading at USD 189.49 on Nasdaq on October 7, 2026, up 1.08 percent from the previous close. The move comes as the company approaches Nasdaq-100 inclusion, while its valuation remains far above the average analyst target.
Revenue rises to USD 145.0 million
According to MarketBeat on October 6, 2026, Moderna reported second-quarter revenue of USD 145.0 million for the quarter ended June 30, 2026. Revenue increased 2.1 percent from USD 142.0 million in the same quarter of 2025, while adjusted loss per share narrowed to USD 1.97 from USD 2.13 and beat the USD 2.03 consensus loss by USD 0.06.
The quarter still carried a heavy earnings burden: Moderna reported a net loss of USD 782.0 million for Q2/2026. The revenue comparison is modest, but the smaller per-share loss gives the current stock rally a concrete operating counterpoint.
Nasdaq-100 date approaches
The Crypto Basic reported on October 6, 2026, that Moderna was scheduled to enter the Nasdaq-100 before the October 9 market open. The same report said the stock had reached USD 203.21 at the October 5 close and traded as high as USD 205.77 during that session.
The index change adds a mechanical demand theme to the biotechnology story, but the price remains below the recent yearly peak. Moderna's current 52-week range is USD 22.28 to USD 212.22, while its market capitalization is USD 75.2 billion as of October 7, 2026.
Targets remain below the stock
The consensus picture is cautious. MarketScreener lists a Hold consensus from 23 analysts, an average price target of USD 119.56, a high target of USD 170.00 and a low target of USD 45.00. The average target sits USD 69.93 below the October 7 Nasdaq price.
MarketBeat also reported that Citigroup cut its rating from Neutral to Sell on September 30, 2026, while raising its target from USD 60.00 to USD 80.00. Goldman Sachs had raised its target from USD 67.00 to USD 120.00 while keeping a Neutral rating on August 19, 2026.
Moderna stock trades above USD 189
Moderna stock was last at USD 189.49 on Nasdaq on October 7, 2026 at 11:09 a.m. ET, with a session range of USD 182.51 to USD 191.30. The combination of Nasdaq-100 visibility, modest revenue growth and targets below the market price leaves clinical execution and future product sales as the key valuation tests.
Moderna stock facts
- Company: Moderna, Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Trading venue: NASDAQ
- Price (as of October 7, 2026, 11:09 a.m. ET): USD 189.49
- Market capitalization: USD 75.2 billion (as of October 7, 2026)
- 52-week range: USD 22.28-212.22 (as of October 7, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: Nasdaq-100
